OncoMatch/Clinical Trials/NCT06961617
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
Is NCT06961617 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LioCyx-M, HBV antigen-specific TCR-redirected T cells for hepatocellular carcinoma.
Treatment: LioCyx-M, HBV antigen-specific TCR-redirected T cells — This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Lab requirements
Liver function
child-pugh a (5 - 7 points)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify